Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The SCOFF questionnaire: a new screening tool for eating disorders
How Much Weight Can You Expect to Lose with the GLP-1 program
confirmed that overexpressed SLC1A3 in gastric cancer activates the PI3K/AKT pathway, upregulates the expression levels of Glucose transporter 1 (GLUT1), Hexokinase 2 (HK2), and Lactate dehydrogenase A (LDHA), and promotes the growth of gastric cancer, while treatment with the PI3K/AKT inhibitor LY294002 could inhibit the growth-promoting effect of SLC1A3 overexpression on gastric cancer
Specification of tissue-resident macrophages during organogenesis
NIDDK-Tirzepatide is a multi-functional treatment solution that primarily helps with weight loss by suppressing appetite and delaying gastric emptying
US$ 21.20
US$ 28.28
US$ 22.49
